南華早報Chinese biotech faces reality check as ArriVent drug failure sinks stock in US
作者 Xinmei Shen
US firm ArriVent BioPharma’s shares plummeted after a late-stage trial failure involving a cancer drug licensed from China, a setback that analysts sa...
US firm ArriVent BioPharma’s shares plummeted after a late-stage trial failure involving a cancer drug licensed from China, a setback that analysts sa...